

## Xeljanz XR - (11 mg; Tablet, Extended Release)

|                              |                                                                                                                                                                                                                                                                               |                             |                     |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Tofacitinib                                                                                                                                                                                                                                                                   | <b>Innovator</b>            | Pfizer              |
| <b>Dosage</b>                | 11 mg; Tablet, Extended Release                                                                                                                                                                                                                                               | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                                                                   | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5                                                                                                                                                                                                                                                                   | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | More Than 5                                                                                                                                                                                                                                                                   | <b>Generic Launches</b>     | Less Than 5         |
| <b>Indication</b>            | Indications for XELJANZ XR: Moderately-to-severely active rheumatoid arthritis (RA) in adults who have had an inadequate response or intolerance to methotrexate (MTX), as monotherapy or in combination with MTX or other nonbiologic disease-modifying anti-rheumatic drugs |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                           |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Xeljanz XR - (22 mg, Tablet; Extended release)

|                              |                                                                                                                                                                                                                 |                             |                     |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Tofacitinib                                                                                                                                                                                                     | <b>Innovator</b>            | Pfizer              |
| <b>Dosage</b>                | 22 mg, Tablet; Extended release                                                                                                                                                                                 | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                     | <b>Known Para IV Filers</b> | More Than 5         |
| <b>Other ANDA developers</b> | More Than 5                                                                                                                                                                                                     | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | Less Than 5                                                                                                                                                                                                     | <b>Generic Launches</b>     | Less Than 5         |
| <b>Indication</b>            | It is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                             |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.